Cambron-Mellott M Janelle, Mikl Jaromir, Matos Joana E, Erensen Jennifer G, Beusterien Kathleen, Cataldo Marc J, Hallissey Bernadette, Mattingly Gregory W
Kantar Health, New York, NY, USA.
Purdue Pharma L.P./Adlon Therapeutics, L.P., Stamford, CT, USA.
Patient Prefer Adherence. 2021 May 21;15:1061-1073. doi: 10.2147/PPA.S311836. eCollection 2021.
Treatment for attention deficit hyperactivity disorder (ADHD) requires a multifaceted approach including psychosocial interventions and pharmacological treatment. This study evaluates preferences for specific attributes associated with different long-acting stimulant treatment among US adults with ADHD.
Patients completed an online, cross-sectional survey, incorporating a discrete choice experiment to assess preferences for attributes.
Analyses included 200 adults with ADHD (mean age 33.0 years; 60% self-reporting moderate severity); the mean (SD) Adult ADHD Self-Report Scale-v1.1 score was 45.9 (12.4). Overall, patients valued speed of onset most and risk of rebound least. Three population groups with distinct preferences were identified: side effect-driven (n=69, 35%), quick onset-driven (n=47, 24%) and quick onset and long duration-driven (n=84, 42%).
This study shows differences in how adults with ADHD value and assess benefit-risk trade-offs when considering the desired attributes of stimulant treatments, highlighting the importance of patient-physician shared decision-making to optimize the desired benefits of individualized treatment.
注意力缺陷多动障碍(ADHD)的治疗需要多方面的方法,包括心理社会干预和药物治疗。本研究评估了美国成年ADHD患者对不同长效兴奋剂治疗相关特定属性的偏好。
患者完成了一项在线横断面调查,其中纳入了一项离散选择实验以评估对属性的偏好。
分析纳入了200名成年ADHD患者(平均年龄33.0岁;60%自我报告为中度严重程度);成人ADHD自我报告量表v1.1的平均(标准差)得分为45.9(12.4)。总体而言,患者最看重起效速度,最不看重反跳风险。确定了三个具有不同偏好的人群组:副作用驱动型(n = 69,35%)、快速起效驱动型(n = 47,24%)和快速起效且持续时间长驱动型(n = 84,42%)。
本研究表明,成年ADHD患者在考虑兴奋剂治疗的期望属性时,对价值的判断和效益风险权衡的评估存在差异,突出了医患共同决策以优化个体化治疗的期望效益的重要性。